Timothy M. Block，宾州，美国——HBV相关实验室及人物介绍系列

bigben446

Timothy M. Block，宾州，美国——HBV相关实验室及人物介绍系列

Timothy M. Block，宾州，美国
Baruch S.Blumberg Institute, Doylestown, PA

Block, T. M. and H. J. Alter, et al. (2016). "A historical perspective on the discovery and elucidation of the hepatitis B virus." Antiviral Res.
Block, T. M. and J. T. Guo (2016). "The Covalently Closed Circular Form of Hepatitis B Virus Genome: Is There Now an  End in "Site"?" Gastroenterology 150(1): 34-6.
Jain, S. and T. T. Chang, et al. (2015). "Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues." Sci Rep 5: 10478.
Guo, F. and Y. Han, et al. (2015). "STING agonists induce an innate antiviral immune response against hepatitis B virus." Antimicrob Agents Chemother 59(2): 1273-81.
Ariza-Mateos, A. and R. Diaz-Toledano, et al. (2015). "Geneticin Stabilizes the Open Conformation of the 5' Region of Hepatitis C Virus  RNA and Inhibits Viral Replication." Antimicrob Agents Chemother 60(2): 925-35.
Gish, R. G. and C. A. Cohen, et al. (2015). "Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States." Hepatology 62(5): 1339-41.
Liang, T. J. and T. M. Block, et al. (2015). "Present and future therapies of hepatitis B: From discovery to cure." Hepatology 62(6): 1893-908.
Yan, R. and X. Zhao, et al. (2015). "The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion." J Virol 89(18): 9200-12.
Block, T. M. and S. Rawat, et al. (2015). "Chronic hepatitis B: A wave of new therapies on the horizon." Antiviral Res 121: 69-81.
Mao, R. and H. Nie, et al. (2013). "Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein." PLoS Pathog 9(7): e1003494.
Cai, D. and H. Nie, et al. (2013). "A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures." Methods Mol Biol 1030: 151-61.
Campagna, M. R. and F. Liu, et al. (2013). "Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids." J Virol 87(12): 6931-42.
Block, T. M. and R. Gish, et al. (2013). "Chronic hepatitis B: what should be the goal for new therapies?" Antiviral Res 98(1): 27-34.
Chang, J. and T. M. Block, et al. (2012). "The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy." Antiviral Res 96(3): 405-13.
Cai, D. and C. Mills, et al. (2012). "Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation." Antimicrob Agents Chemother 56(8): 4277-88.
Nie, H. and A. A. Evans, et al. (2012). "Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion." J Hepatol 56(4): 795-802.
Liu, Y. and J. S. Testa, et al. (2011). "A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation." PLoS One 6(9): e24477.
Yu, W. and C. Goddard, et al. (2011). "Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion." J Med Chem 54(16): 5660-70.
Nie, H. and A. A. Evans, et al. (2011). "Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis." J Clin Virol 51(4): 234-40.
Nie, H. and A. A. Evans, et al. (2011). "Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach." J Clin Microbiol 49(7): 2440-8.
Mao, R. and J. Zhang, et al. (2011). "Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells." J Virol 85(2): 1048-57.
Cohen, C. and S. D. Holmberg, et al. (2011). "Is chronic hepatitis B being undertreated in the United States?" J Viral Hepat 18(6): 377-83.
Norton, P. A. and S. Menne, et al. (2010). "Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks." Hepatology 52(4): 1242-50.
Xu, C. and H. Guo, et al. (2010). "Interferons accelerate decay of replication-competent nucleocapsids of hepatitis  B virus." J Virol 84(18): 9332-40.
Lamontagne, J. and M. Pinkerton, et al. (2010). "Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis." J Virol 84(2): 907-17.
Ren, X. D. and S. Y. Lin, et al. (2009). "Rapid and sensitive detection of hepatitis B virus 1762T/1764A double mutation from hepatocellular carcinomas using LNA-mediated PCR clamping and hybridization  probes." J Virol Methods 158(1-2): 24-9.
Simsek, E. and G. Sinnathamby, et al. (2009). "Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I." Virology 384(1): 12-5.
Guo, H. and D. Jiang, et al. (2009). "Activation of pattern recognition receptor-mediated innate immunity inhibits the  replication of hepatitis B virus in human hepatocyte-derived cells." J Virol 83(2): 847-58.
Chang, J. and J. T. Guo, et al. (2008). "Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in  nonhepatic cells." J Virol 82(16): 8215-23.
Balagopal, A. and F. H. Philp, et al. (2008). "Human immunodeficiency virus-related microbial translocation and progression of hepatitis C." Gastroenterology 135(1): 226-33.
Hann, H. W. and S. H. Han, et al. (2008). "Symptomatology and health attitudes of chronic hepatitis B patients in the USA." J Viral Hepat 15(1): 42-51.
Jiang, D. and H. Guo, et al. (2008). "Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus." J Virol 82(4): 1665-78.
Mehta, A. S. and R. E. Long, et al. (2008). "Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of  hepatitis C virus-infected individuals with fibrosis and cirrhosis." J Virol 82(3): 1259-70.
Block, T. M. and H. Guo, et al. (2007). "Molecular virology of hepatitis B virus for clinicians." Clin Liver Dis 11(4): 685-706, vii.
Guo, H. and D. Jiang, et al. (2007). "Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation." J Virol 81(22): 12472-84.
Guo, H. and T. Zhou, et al. (2007). "Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway." J Virol 81(18): 10072-80.
Simsek, E. and X. Lu, et al. (2006). "alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis  B virus through the sustained inhibition of the large and middle envelope glycoproteins." Antivir Chem Chemother 17(5): 259-67.
Zhou, T. and H. Guo, et al. (2006). "Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays." Antiviral Res 72(2): 116-24.
Block, T. M. and A. S. Mehta, et al. (2006). "Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity?" DNA Cell Biol 25(3): 165-70.
Schwegler, E. E. and L. Cazares, et al. (2005). "SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma." Hepatology 41(3): 634-42.
Block, T. M. and W. T. London (2004). "Surrogate markers of efficacy for medical treatment of viral hepatitis." Biotechnol Healthc 1(5): 42-8.
Mehta, A. S. and B. Gu, et al. (2004). "alpha-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses." Antimicrob Agents Chemother 48(6): 2085-90.
Comunale, M. A. and T. S. Mattu, et al. (2004). "Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status." Proteomics 4(3): 826-38.
Lu, X. and T. Tran, et al. (2003). "The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture." J Virol 77(22): 11933-40.
Norton, P. A. and Q. Gong, et al. (2003). "Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells." J Virol 77(9): 5503-6.
Mehta, A. and B. Conyers, et al. (2002). "Structure-activity relationship of a new class of anti-hepatitis B virus agents." Antimicrob Agents Chemother 46(12): 4004-8.
Ouzounov, S. and A. Mehta, et al. (2002). "The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy." Antiviral Res 55(3): 425-35.
Block, T. M. and R. Jordan (2001). "Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs." Antivir Chem Chemother 12(6): 317-25.
Lu, X. and Y. Lu, et al. (2001). "Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-mediated processing in the endoplasmic reticulum." DNA Cell Biol 20(10): 647-56.
Mehta, A. and S. Carrouee, et al. (2001). "Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications." Hepatology 33(6): 1488-95.
Zitzmann, N. and A. S. Mehta, et al. (1999). "Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus,  a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents." Proc Natl Acad Sci U S A 96(21): 11878-82.
Block, T. M. and X. Lu, et al. (1998). "Role of glycan processing in hepatitis B virus envelope protein trafficking." Adv Exp Med Biol 435: 207-16.
Mehta, A. and T. M. Block, et al. (1998). "The role of N-linked glycosylation in the secretion of hepatitis B virus." Adv Exp Med Biol 435: 195-205.
Lu, X. and A. Mehta, et al. (1997). "Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited." Proc Natl Acad Sci U S A 94(6): 2380-5.
Mehta, A. and X. Lu, et al. (1997). "Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion." Proc Natl Acad Sci U S A 94(5): 1822-7.
Lu, X. and T. M. Block, et al. (1996). "Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line." J Virol 70(4): 2277-85.
Block, T. M. and X. Lu, et al. (1994). "Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin." Proc Natl Acad Sci U S A 91(6): 2235-9.